Novartis presents promising new data on treatment for relapsing MS
Data showed that continuous treatment with Kesimpta was associated with fewer relapses and reduced risk of disability worsening
Novartis has presented new data that demonstrates the long-term efficacy and safety of its monoclonal antibody Kesimpta (ofatumumab) in people living with relapsing multiple sclerosis following up to four years of treatment.
The long-term data comes from the company's Phase 3 Asclepios I/II trials and Alithios open-label extension. Kesimpta maintained a similar safety profile as seen in Phase 3 trials, with no new safety risks identified over the four-year treatment period.
Kesimpta was approved by the US Food and Drug Administration (FDA) in August, 2020.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by myelin destruction and axonal damage in the brain, optic nerves and spinal cord. It affects approximately 2.3 million people worldwide. Relapsing MS is a form of the disease where patients have relapses (symptoms worsen) and periods of stability in between relapses.
In addition to demonstrating efficacy with four years of continuous treatment with Kesimpta, participants who switched from teriflunomide, an oral medication, to Kesimpta in the extension phase saw significant reductions in relapses and MRI lesions.
Novartis Global Medical Franchise Head, Lykke Hinsch Gylvin, said the data supports Kesimpta as an “efficacious and well-tolerated" option for people living with relapsing MS.
She said: “The sustained reductions in disability progression and lesion activity observed in those receiving continuous Kesimpta versus those who switched later from teriflunomide highlight the value of earlier treatment initiation with Kesimpta”.
Additionally, data from the ongoing KYRIOS open-label, prospective study shows that people taking Kesimpta for MS can mount an immune response to mRNA COVID-19 vaccines. All participants in the study who were vaccinated during continuous Kesimpta treatment developed an immune response as soon as one week after initial vaccination.
The FDA has approved more than a dozen medications for the treatment of relapsing forms of MS, which include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance